US8101743 — Modulation of transthyretin expression
Composition of Matter · Assigned to Isis Pharmaceuticals Inc · Expires 2026-04-01 · 0y expired
What this patent protects
This patent protects compounds, compositions, and methods for modulating the expression of transthyretin using oligonucleotides targeted to nucleic acid encoding transthyretin.
USPTO Abstract
Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.